View Older Stories View More Recent Stories

Oct 31, 2019 06:00AM Novocure Reports Third Quarter 2019 Financial Results and Provides Company Update
Oct 1, 2019 04:30PM Paratek Announces Inducement Grants under NASDAQ Listing Rule 5635(c)(4)
Sep 5, 2019 06:40AM Companies with NDRs 09/05
Sep 4, 2019 06:42AM Companies with NDRs 09/04
Aug 12, 2019 07:34AM Zai Lab (ZLAB) and Novocure (NVCR) Announces China NMPA Granted Innovative Medical Device Designation for Optune
Aug 12, 2019 07:30AM China National Medical Products Administration Grants Innovative Medical Device Designation for Optune® in China
Aug 12, 2019 07:30AM China National Medical Products Administration Grants Innovative Medical Device Designation for Optune® in China
Aug 12, 2019 07:30AM China National Medical Products Administration Grants Innovative Medical Device Designation for Optune® in China
Aug 1, 2019 04:05PM Paratek Announces Inducement Grants under NASDAQ Listing Rule 5635(c)(4)
Jul 25, 2019 06:00AM Novocure Reports Second Quarter 2019 Financial Results and Provides Company Update
Jul 2, 2019 07:32AM Incyte (INCY), Zai Lab Announce Collaboration and License Agreement for INCMGA0012 in Greater China
Jul 2, 2019 07:30AM Incyte and Zai Lab Announce Collaboration and License Agreement for INCMGA0012 in Greater China
Jul 2, 2019 07:30AM Incyte and Zai Lab Announce Collaboration and License Agreement for INCMGA0012 in Greater China
Jul 2, 2019 07:30AM Incyte and Zai Lab Announce Collaboration and License Agreement for INCMGA0012 in Greater China
May 8, 2019 04:05PM Five Prime Therapeutics Reports First Quarter 2019 Results
May 2, 2019 06:00AM Novocure Reports First Quarter 2019 Financial Results and Provides Company Update
Mar 1, 2019 04:30PM Paratek Announces Inducement Grants under NASDAQ Listing Rule 5635(c)(4)
Feb 27, 2019 04:01PM Paratek Pharmaceuticals Reports Fourth Quarter and Full Year 2018 Financial Results
Feb 26, 2019 04:05PM Five Prime Therapeutics Reports Fourth Quarter and Full Year 2018 Financial Results
Feb 6, 2019 05:05PM New England Journal of Medicine Publishes Results from Pivotal Phase 3 Studies of Paratek’s NUZYRA™ (Omadacycline) For Pneumonia and Skin Infections
Feb 5, 2019 04:05PM Paratek Pharmaceuticals Launches NUZYRA™ (Omadacycline) in the United States
Jan 14, 2019 06:41PM Five Prime Therapeutics Announces Two Poster Presentations at the 2019 Gastrointestinal Cancers Symposium
Nov 14, 2018 07:30AM Zai Lab and Novocure Awarded Deal of the Year
Nov 14, 2018 07:30AM Novocure and Zai Lab Awarded Deal of the Year at 5th Annual BioCentury China Healthcare Summit in Shanghai, China
Nov 14, 2018 07:30AM Zai Lab and Novocure Awarded Deal of the Year
Nov 7, 2018 04:00PM Novocure and Zai Lab to Host Investor Event
Nov 6, 2018 04:05PM Five Prime Therapeutics Announces Third Quarter 2018 Financial Results
Nov 6, 2018 04:02PM Paratek Pharmaceuticals Reports Third Quarter 2018 Financial Results
Nov 1, 2018 04:05PM TESARO Announces Third-Quarter 2018 Operating Results
Oct 26, 2018 04:05PM Paratek Pharmaceuticals to Report Third Quarter 2018 Financial Results on November 6, 2018
Oct 25, 2018 06:00AM Novocure Reports Third Quarter 2018 Financial Results and Provides Company Update
Oct 11, 2018 09:01AM MMS Submission Support for Paratek Pharmaceuticals Garners FDA Approval and Successful MAA Filing of NUZYRA™ (Omadacycline)
Oct 1, 2018 08:02AM Five Prime Therapeutics (FPRX), Zai Lab Limited (ZLAB) Report First Patient Dosed in Phase 3 FIGHT Pivotal Trial of Bemarituzumab (FPA144)
Oct 1, 2018 08:00AM Five Prime Therapeutics and Zai Lab Dosed First Patient in Phase 3, Global Registrational Trial of Bemarituzumab in Front-Line Advanced Gastric and Gastroesophageal Junction Cancers
Sep 25, 2018 08:00AM Paratek Pharmaceuticals Presenting New Omadacycline Data at IDWeek 2018
Sep 12, 2018 07:34AM Novocure (NVCR), Zai Lab (ZLAB) Announce Strategic Collaboration with License Agreement for Tumor Treating Fields in Greater China
Sep 12, 2018 07:30AM Novocure and Zai Lab Announce Strategic Collaboration with a License Agreement for Tumor Treating Fields in Greater China
Sep 10, 2018 09:04AM Five Prime Therapeutics (FPRX) Reports Complete Phase 1 Safety Lead-In and Initiates Phase 3 of FIGHT Phase 1/3 Clinical Trial of Bemarituzumab (FPA144)
Sep 10, 2018 09:00AM Five Prime Therapeutics Completes Phase 1 Safety Lead-In and Initiates Phase 3, Global Registrational Trial of Bemarituzumab in Front-Line Advanced Gastric and Gastroesophageal Junction Cancers
Aug 29, 2018 04:05PM Paratek Pharmaceuticals to Present at Baird's 2018 Global Healthcare Conference
Aug 8, 2018 04:05PM Five Prime Therapeutics Announces Second Quarter 2018 Financial Results
Aug 8, 2018 02:21PM Paratek Pharmaceuticals (PRTK) Confirms Positive FDA Ad Comm Recommendation for Omadacycline
Aug 8, 2018 02:20PM FDA Advisory Committee Recommends Approval of Paratek’s Omadacycline
Aug 2, 2018 04:01PM Paratek Pharmaceuticals Reports Second Quarter 2018 Financial Results
Jun 4, 2018 06:45AM Five Prime Therapeutics (FPRX) Announces Bemarituzumab Trial-in-Progress Poster at 2018 ASCO Meeting
Jun 3, 2018 09:00AM Five Prime Therapeutics Presents Bemarituzumab Trial-in-Progress Poster at the 2018 ASCO Annual Meeting
May 30, 2018 04:09PM Five Prime Therapeutics (FPRX) Announces Pact with Roche to Develop Companion Diagnostics for Targeted Immuno-Oncology Investigational Drug Candidates
May 30, 2018 04:05PM Five Prime Therapeutics Announces Collaboration with Roche to Develop Companion Diagnostics for Targeted Immuno-Oncology Investigational Drug Candidates
May 9, 2018 07:30AM Paratek Pharmaceuticals Reports First Quarter 2018 Financial Results
May 8, 2018 04:05PM Five Prime Therapeutics Announces First Quarter 2018 Financial Results
View More Recent Stories View Older Stories